Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi SyndromeGlobeNewsWire • 12/10/25
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug ProgressSeeking Alpha • 11/25/25
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025GlobeNewsWire • 11/10/25
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 MillionThe Motley Fool • 11/08/25
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic ObesityGlobeNewsWire • 11/07/25
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits ProgramGlobeNewsWire • 11/05/25
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/25
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 11/04/25
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025GlobeNewsWire • 10/21/25
Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic ObesityGlobeNewsWire • 08/20/25
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 08/05/25
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/25
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025GlobeNewsWire • 07/22/25
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025GlobeNewsWire • 07/12/25
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity MarketSeeking Alpha • 07/10/25
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study DataZacks Investment Research • 07/10/25